Figure 2. Reversal of hemoglobin switching to induce therapeutic levels of HbF. Reversal of hemoglobin switching can be accomplished through autologous bone marrow transplantation of genome-edited CD34+ HSPCs. The gray region indicates the hypothesized levels of HbF required for clinical benefit.
Figure 2

Reversal of hemoglobin switching to induce therapeutic levels of HbF. Reversal of hemoglobin switching can be accomplished through autologous bone marrow transplantation of genome-edited CD34+ HSPCs. The gray region indicates the hypothesized levels of HbF required for clinical benefit.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal